Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modified FOLFOX6 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Modified FOLFOX6 + bevacizumab is a combination chemotherapy regimen primarily used for the treatment of advanced or metastatic colorectal cancer. The "modified FOLFOX6" component consists of oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU) administered in specific doses and schedules that differ slightly from the original FOLFOX regimens. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), is added to inhibit tumor angiogenesis. The mechanism of action involves cytotoxic effects on rapidly dividing cells by the chemotherapeutic agents and inhibition of blood vessel formation by bevacizumab, thereby restricting tumor growth and metastasis[1][4][8]. This regimen is considered standard first-line therapy for metastatic colorectal cancer.
- Other names
- mFOLFOX6 plus bevacizumabmFOLFOX-6 plus bevacizumabmFOLFOX 6 plus bevacizumabmodified FOLFOX6 plus bevacizumab
02
Targets
Beyond the preview
Go deeper on modified FOLFOX6 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modified FOLFOX6 + bevacizumab.